The Manufacturers Life Insurance Company Buys Shares of 11,427 Sera Prognostics, Inc. (NASDAQ:SERA)

The Manufacturers Life Insurance Company purchased a new position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,427 shares of the company’s stock, valued at approximately $68,000.

A number of other large investors have also added to or reduced their stakes in SERA. Lake Street Advisors Group LLC acquired a new position in Sera Prognostics in the 2nd quarter valued at approximately $144,000. American Century Companies Inc. increased its holdings in Sera Prognostics by 12.7% in the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after purchasing an additional 2,891 shares during the period. Renaissance Technologies LLC bought a new position in Sera Prognostics during the 2nd quarter worth $162,000. Rhumbline Advisers acquired a new position in Sera Prognostics during the 2nd quarter worth about $190,000. Finally, Sanders Morris Harris LLC lifted its holdings in Sera Prognostics by 82.2% during the 2nd quarter. Sanders Morris Harris LLC now owns 34,800 shares of the company’s stock worth $206,000 after buying an additional 15,700 shares during the period. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics Trading Down 4.6 %

Shares of SERA stock opened at $7.32 on Tuesday. The stock has a 50-day moving average of $7.30 and a 200-day moving average of $7.94. The stock has a market cap of $244.27 million, a price-to-earnings ratio of -7.47 and a beta of 1.03. Sera Prognostics, Inc. has a 1-year low of $1.56 and a 1-year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.08 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. Sell-side analysts forecast that Sera Prognostics, Inc. will post -0.95 earnings per share for the current year.

Insider Activity

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 12,327 shares of Sera Prognostics stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total value of $91,466.34. Following the completion of the sale, the chief executive officer now directly owns 856,918 shares in the company, valued at approximately $6,358,331.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider John J. Boniface sold 5,022 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total transaction of $37,263.24. Following the transaction, the insider now owns 129,847 shares in the company, valued at approximately $963,464.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Zhenya Lindgardt sold 12,327 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $91,466.34. Following the completion of the sale, the chief executive officer now owns 856,918 shares of the company’s stock, valued at approximately $6,358,331.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 54,543 shares of company stock valued at $409,179 in the last ninety days. 15.80% of the stock is owned by company insiders.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.